Point Biopharma Global Stock Target Price
| PNTDelisted Stock | USD 9.06 0.10 1.09% |
POINT Biopharma Global fundamentals help investors to digest information that contributes to POINT Biopharma's financial success or failures. It also enables traders to predict the movement of POINT Stock. The fundamental analysis module provides a way to measure POINT Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to POINT Biopharma stock.
POINT |
POINT Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses POINT Biopharma's direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of POINT Biopharma could also be used in its relative valuation, which is a method of valuing POINT Biopharma by comparing valuation metrics of similar companies.POINT Biopharma is currently under evaluation in target price category among its peers.
POINT Fundamentals
| Return On Equity | 0.26 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.40 % | |||
| Operating Margin | (10.62) % | |||
| Current Valuation | 1 B | |||
| Shares Outstanding | 106.57 M | |||
| Shares Owned By Insiders | 14.97 % | |||
| Shares Owned By Institutions | 48.91 % | |||
| Number Of Shares Shorted | 2.64 M | |||
| Price To Book | 3.13 X | |||
| Price To Sales | 5.45 X | |||
| Revenue | 226.58 M | |||
| EBITDA | 127.32 M | |||
| Net Income | 98.29 M | |||
| Cash And Equivalents | 199.43 M | |||
| Cash Per Share | 2.21 X | |||
| Total Debt | 3.56 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 10.90 X | |||
| Book Value Per Share | 4.01 X | |||
| Cash Flow From Operations | 183.52 M | |||
| Short Ratio | 0.98 X | |||
| Earnings Per Share | 1.10 X | |||
| Target Price | 12.5 | |||
| Number Of Employees | 129 | |||
| Beta | -0.003 | |||
| Market Capitalization | 1.33 B | |||
| Total Asset | 578.32 M | |||
| Retained Earnings | 39.01 M | |||
| Working Capital | 451.08 M | |||
| Net Asset | 578.32 M |
About POINT Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze POINT Biopharma Global's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of POINT Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of POINT Biopharma Global based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in POINT Stock
If you are still planning to invest in POINT Biopharma Global check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the POINT Biopharma's history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |